Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Key Highlights
- ➤EVX-01 phase 2 data to include broad systemic immune-modulation analysis
- ➤EVX-01 plus pembrolizumab produced 75% ORR at two-year follow-up
- ➤12 of 16 advanced melanoma patients achieved objective clinical responses
- ➤Four patients achieved complete responses at two-year follow-up
- ➤89% of EVX-01 neoantigen targets triggered tumor-specific immune responses
Expert Statements
Mads Lausen, Senior Scientist at Evaxion
“EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma”
* New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.
The new data includes analysis of broad systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses. It will be presented in both an oral and poster session at the SITC meeting.
Get started
Create a free account to read the full story.